Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck

Nadeem Riaz, Eric Sherman, Lawrence Koutcher, Lauren Shapiro, Nora Katabi, Zhigang Zhang, Weiji Shi, Mathew Fury, Richard Wong, Suzanne Wolden, Shyam Rao, Nancy Lee

Research output: Contribution to journalArticle

33 Scopus citations

Abstract

Objectives: We previously reported inferior outcomes for locally advanced head and neck cancer treated with cetuximab (C225) versus cisplatin (CDDP). We now examine if this difference persists when accounting for HPV status and update outcomes on the entire cohort. Materials and Methods: From 3/106 to 4/1/08, 174 locally advanced head and neck cancer patients received definitive treatment with RT and CDDP (n = 125) or RT and C225 (n = 49). Of these, 62 patients had tissue available for HPV analysis. Results: The median follow-up was 47 months. The 3-year locoregional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.7% versus 40.2% (P < 0.0001), 85.1% versus 35.4% (P < 0.0001), and 90.0% versus 56.6% (P < 0.0001), respectively. In the subset with tissue, there was no difference in rates of HPV or p16 positivity between the 2 groups. In this subset, the 3-year loco-regional failure, disease-free survival, and overall survival for CDDP versus C225 were 5.3% versus 32.0% (P = 0.01), 86.8% versus 43.2% (P = 0.002), and 86.7% versus 76.9% (P = 0.09), respectively. Multivariate analysis continued to show a benefit for CDDP. Conclusions: With longer follow-up and the inclusion of HPV and p16 status for about one third of patients where tissue was available, we continued to find superior outcomes with concurrent CDDP versus C225.

Original languageEnglish (US)
Pages (from-to)27-31
Number of pages5
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume39
Issue number1
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Keywords

  • Cetuximab
  • Cisplatin
  • Head and neck cancer
  • HPV
  • Radiation

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck'. Together they form a unique fingerprint.

  • Cite this

    Riaz, N., Sherman, E., Koutcher, L., Shapiro, L., Katabi, N., Zhang, Z., Shi, W., Fury, M., Wong, R., Wolden, S., Rao, S., & Lee, N. (2016). Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck. American Journal of Clinical Oncology: Cancer Clinical Trials, 39(1), 27-31. https://doi.org/10.1097/COC.0000000000000006